These innovative compounds represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://zubairrwwo896751.losblogos.com/37999845/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide